Press Releases

May 05, 2022
SIGA Reports Financial Results for Three Months Ended March 31, 2022
- First Sale of Intravenous (IV) TPOXX® to U.S. Government under the 19C BARDA Contract – - Contract with a New International Jurisdiction for an Initial Order of Approximately $3 Million of Oral TPOXX - - Corporate Update Conference Call Today at 4:30 PM ET   - NEW YORK , May 05, 2022 (GLOBE
May 05, 2022
SIGA Declares Special Dividend of $0.45 Per Share
NEW YORK , May 05, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that the Board of Directors declared a special dividend of $0.45 per share on the common stock of the Company.
Jan 25, 2022
SIGA Announces Preclinical Oncology Research Collaboration with Bioarchitech
Investigating TPOXX® in Combination with Bioarchitech’s Oncolytic Vaccinia Immunotherapy Platform NEW YORK , Jan. 25, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it
Displaying 1 - 10 of 11